XVIVO

XVIVO describes itself as the only medical technology company dedicated to extending the life of all major organs. Its portfolio spans heart, lung, liver and kidney preservation, assessment and transport solutions used by transplant teams worldwide.

The company combines device sales with disposable products and transplant support services for hospitals. This installed-base model, paired with regulatory approvals including CE certificates for heart preservation technology, underpins recurring revenue.

XVIVO is the European market leader in liver machine perfusion, supported by clinical data published in leading scientific journals. In the United States the company is pursuing FDA premarket approval for both its heart preservation technology and its Liver Assist platform.

Regulatory progress continued with the FDA granting approval to include donation-after-circulatory-death hearts in the investigational device exemption trial. The company is scaling disposable production to secure delivery capacity as the installed base grows.

XVIVO is headquartered in Gothenburg, Sweden, with offices and research sites on two continents. The group employs approximately 210 people across its development, production and commercial operations.

Its business concept is to develop and market technologies for preserving, assessing and transporting organs outside the body while awaiting transplant. The company also offers service solutions that support hospitals through the transplant process.